<DOC>
	<DOCNO>NCT00656370</DOCNO>
	<brief_summary>Randomized , double-blinded study evaluate tolerability , safety , flow rate different solution subcutaneously ( SC ) infuse preceded human recombinant hyaluronidase ( hylenex ) 150 unit . In Stage 1 , comparison Normal Saline ( NS ) solution Lactated Ringer 's ( LR ) solution . Each subject receive 500 milliliter ( mL ) solution , consist NS one thigh LR thigh . Immediately prior infusion , thigh 150 unit hylenex . In Stage 2 , comparison NS solution buffer NS solution .</brief_summary>
	<brief_title>Study Subcutaneous Hydration Enabled Human Recombinant Hyaluronidase ( Hylenex )</brief_title>
	<detailed_description>This Phase IV , randomize , double-blinded study volunteer subject evaluate tolerability , safety , flow rate different solution subcutaneously ( SC ) infuse preceded human recombinant hyaluronidase ( hylenex ) 150 unit . The study conduct two sequential stage . In Stage 1 , comparison NS solution LR solution . Each subject receive simultaneous SC infusion 500 mL ( 500 mL bag ) solution anterior thigh , consist NS one thigh LR thigh . The thigh ( leave vs. right ) receive NS LR randomize double blind . Immediately prior infusion , thigh 150 unit hylenex simultaneously inject . Tolerability assess base subject 's self-assessment discomfort visual analog scale ( VAS ) . Safety assess physical examination target infusion site , vital sign , adverse event . The amount fluid infuse assessed weigh infusion bag , fluid tube designated time point , allow determination flow rate . Stage 2 conduct observed Stage 1 VAS mean maximum pain score least 25 mm high one solution compare . Stage 2 evaluate tolerability , safety , flow rate subcutaneously infused NS solution buffer NS solution .</detailed_description>
	<criteria>1 . Male female , 18 60 year age . 2 . Intact normal skin without area intend infusion . 3 . No fluid intake 12 hour prior start study infusion . 4 . Vital sign ( Blood Pressure ( BP ) , Heart Rate ( HR ) , Respiratory Rate ( RR ) ) within normal range . 5 . Metabolic panel within normal range . 6 . A negative urine serum pregnancy test . 7 . Signed , write Institutional Review Board ( IRB ) approve informed consent . 1 . Lower extremity edema . 2 . Lower extremity pathology could interfere study outcome . 3 . Rales lung auscultation . 4 . History cardiovascular disease . 5 . Allergy hyaluronidase . 6 . Allergy bee vespid venom . 7 . Pregnancy breastfeed woman . 8 . Use investigational drug device within 30 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Hylenex</keyword>
	<keyword>subcutaneous infusion</keyword>
	<keyword>hyaluronidase</keyword>
	<keyword>rHuPH20</keyword>
	<keyword>recombinant human hyaluronidase</keyword>
</DOC>